Rifaximin for the Secondary Prevention of Recurrent Pouchitis

NCT06312683 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Pouchitis

Interventions

DRUG: Rifaximin 550 MG Oral Tablet [XIFAXAN]

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]